PPMonitor checks laboratory air quality

Published: 12-Apr-2010
Design & Build HVAC Regulatory

Enables effective and flexible management of indoor air quality

PPM Technology’s wireless IAQ profile PPMonitor enables simple, effective and flexible management of the indoor air environment of a laboratory or cleanroom.

The PPMonitor, from the Caernarfon, Wales firm, can continuously detect, measure and record temperature, humidity, formaldehyde, nitrogen dioxide, carbon monoxide, carbon dioxide, sulphur dioxide, ozone, ammonia and TVOCs.

The device incorporates a variety of advanced gas sensor technologies to monitor the target gases including NDIR, PID and electrochemical sensors.

The wireless units communicate via the Zigbee wireless mesh network, which can be extended by adding repeater nodes or additional PPMonitor or Mini PPMonitor units. Each unit can be configured with unique sensor specifications if required, allowing complete monitoring of the cleanroom air environment.

PPMonitor Units can be wirelessly connected to a Building Management System, in which BMS software allows the entire wireless system to be managed from a single PC. The BMS can activate and control air conditioning and ventilation systems; it can also turn on/off heating and trigger building alarms, if required.

All recorded data is stored automatically with dedicated software, which enables the data to be viewed graphically and produces reports and statistical data. Analysis of the recorded data over time allows for more efficient management of resources and energy.

See more

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

Read more
The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway

Trending Articles

  1. NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
  2. CDA-AMC rejects Leqembi reimbursement despite Health Canada approval After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
  3. Johnson & Johnson files FDA application for IMAAVY in wAIHA Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
  4. IMed Group appoints Spencer Keegan as Talent Acquisition Manager IMed confirms expansion of business and implements new recruitment services for clients
  5. Navigating AI regulation for digital medical devices in global markets New whitepaper outlines regulatory pathways for AI-powered medical technologies in the UK, US and EU

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Regulatory

Shield Therapeutics’ ACCRUFeR becomes first FDA-approved oral iron for children 10+

The FDA's approval for ACCRUFeR (ferric maltol) to treat iron deficiency in children aged 10 and older makes it the first and only prescription oral iron therapy specifically approved for this pediatric population
Regulatory

Hansa Biopharma’s imlifidase BLA accepted for FDA review

The US Food and Drug Administration has accepted the company's Biologics License Application for imlifidase, a novel IgG-cleaving enzyme designed to enable HLA-incompatible kidney transplantation
Subscribe now